These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 30341682)

  • 1. Pyrotinib: First Global Approval.
    Blair HA
    Drugs; 2018 Nov; 78(16):1751-1755. PubMed ID: 30341682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report.
    Dai J; Chen Y; Tang C; Wei X; Gong Y; Wei J; Gu D; Chen J
    Medicine (Baltimore); 2020 Jun; 99(25):e20809. PubMed ID: 32569228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients.
    Tian W; Hao S; Wang L; Chen Y; Li Z; Luo D
    Anticancer Drugs; 2022 Jan; 33(1):e622-e627. PubMed ID: 34407046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
    Wang C; Zhou Y; Lin Y; Mao F; Guan J; Zhang X; Shen S; Wang X; Zhang Y; Pan B; Zhong Y; Peng L; Cao X; Yao R; Zhou X; Xu C; Xu Y; Sun Q
    BMC Cancer; 2022 Mar; 22(1):269. PubMed ID: 35287613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
    Li X; Yang C; Wan H; Zhang G; Feng J; Zhang L; Chen X; Zhong D; Lou L; Tao W; Zhang L
    Eur J Pharm Sci; 2017 Dec; 110():51-61. PubMed ID: 28115222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.
    Lv F; Cao J; Liu Z; Wang Z; Zhang J; Zhang S; Wang L; Zhao X; Shao Z; Wang B; Hu X
    PLoS One; 2015; 10(3):e0118607. PubMed ID: 25768439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
    Zhu W; Wu J; Cui M; Zhang L
    Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrotinib versus lapatinib in HER2-positive breast cancer.
    Gourd E
    Lancet Oncol; 2019 Oct; 20(10):e562. PubMed ID: 31477452
    [No Abstract]   [Full Text] [Related]  

  • 17. Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer.
    Wen HN; Liu YX; Xu D; Zhao KJ; Jiao Z
    Eur J Pharm Sci; 2021 Apr; 159():105729. PubMed ID: 33484815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
    Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
    Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.